They reported about significantly better 3-year survival rate in the sirolimus-group (86%) compared to the Tac-population (56%; P = 0.04), although risk profiles with respect to MVI, poor tumor grading, and AFP levels were not different between the patients [259]. The gene discussed is AFP; the disease is neoplasm.